证券代码：603079 证券简称：圣达生物 公告编号：2025-059 浙江圣达生物药业股份有限公司 关于2024年员工持股计划完成非交易过户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 户至本员工持股计划名下之日起计算。本员工持股计划通过非交易过户等法律法 规允许的方式获得公司回购专用证券账户所持有的公司股票，自公司公告最后一 笔标的股票过户至本员工持股计划名下之日起12个月后开始分三期解锁，解锁时 点分别为自公司公告最后一笔标的股票过户至本员工持股计划名下之日起计算满 12个月后、24个月后、36个月后，每期解锁的标的股票比例分别为30%、30%、 40%。锁定期内，因公司分配股票股利、资本公积转增股本等情形所衍生取得的股 份，亦应遵守上述股份锁定安排。 公司将持续关注本员工持股计划的实施进展情况，并按照相关法律法规规定 及时履行信息披露义务。敬请广大投资者注意投资风险。 特此公告。 浙江圣达生物药业股份有限公司董事会 2025年10月31日 浙江圣达生物药业股份有限公司（以下简称"公司"）于2025年4月24日 ...

Core Insights - The report indicates that as of October 29, 2025, a total of 9 institutional investors hold shares in Shengda Bio (603079.SH), with a combined holding of 98.73 million shares, representing 52.23% of the company's total equity [1] - The institutional holding ratio has increased by 0.05 percentage points compared to the previous quarter [1] - In terms of public funds, 18 public funds have not disclosed their holdings this quarter, including notable funds such as CITIC Prudential Multi-Strategy Mixed (LOF) A and others [1] Institutional Holdings - 9 institutional investors disclosed their holdings in Shengda Bio, with a total of 98.73 million shares [1] - The institutional investors include Zhejiang Shengda Group Co., Ltd., Tian Tai Wan Jian Investment Development Center (Limited Partnership), and several private equity funds [1] - The total institutional holding ratio stands at 52.23%, reflecting a slight increase from the previous quarter [1] Public Fund Holdings - 18 public funds did not disclose their holdings this quarter, which includes funds like CITIC Prudential Multi-Strategy Mixed (LOF) A and others [1] - The lack of disclosure from these public funds may indicate a stable investment strategy or a lack of significant changes in their positions [1]

Core Insights - The company reported a third-quarter revenue of 221 million yuan, representing a year-on-year decline of 1.71% [1] - The net profit attributable to shareholders reached 15.53 million yuan, showing a significant year-on-year increase of 199.63% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 12.43 million yuan, reflecting a year-on-year growth of 178.52% [1] - The basic earnings per share stood at 0.08 yuan [1]

Financial Performance - The company's operating revenue for Q3 2025 was CNY 220,554,157.85, a decrease of 1.71% compared to the same period last year[4] - The total profit for the period reached CNY 21,833,992.24, an increase of 98.24% year-on-year[4] - The net profit attributable to shareholders was CNY 15,533,173.25, reflecting a significant increase of 199.63% compared to the previous year[4] - The net profit after deducting non-recurring gains and losses was CNY 12,428,904.17, up by 178.52% year-on-year[4] - Basic earnings per share for the period were CNY 0.08, representing a 166.67% increase compared to the same period last year[5] - Operating profit for the first three quarters of 2025 was ¥72,240,018.70, significantly higher than ¥28,224,215.73 in 2024, marking an increase of approximately 156.8%[23] - Net profit for the first three quarters of 2025 was ¥58,727,071.15, compared to ¥27,409,202.51 in 2024, reflecting an increase of around 114.1%[24] - Basic and diluted earnings per share for the first three quarters of 2025 were both ¥0.30, up from ¥0.13 in 2024, indicating a growth of approximately 130.8%[24] Assets and Liabilities - Total assets at the end of the period were CNY 2,146,271,646.96, a growth of 20.22% compared to the end of the previous year[5] - The total assets of the company amounted to ¥2,146,271,646.96, compared to ¥1,785,311,152.08 in the previous year, showing an increase of approximately 20.2%[21] - Total liabilities increased to ¥542,146,910.35 in 2025 from ¥501,336,831.71 in 2024, reflecting a growth of about 8.1%[21] - The company's equity rose to ¥1,604,124,736.61 in 2025, up from ¥1,283,974,320.37 in 2024, indicating an increase of approximately 25%[21] Cash Flow - Operating cash inflow from sales increased to $639.34 million, up from $601.48 million, representing a growth of approximately 6.3%[27] - Net cash flow from operating activities decreased to $67.66 million from $81.27 million, a decline of about 16.6%[27] - Cash inflow from investment activities surged to $1.04 billion, compared to $108.20 million, indicating a significant increase[28] - Net cash flow from investment activities was negative at -$110.48 million, an improvement from -$215.60 million[28] - Cash inflow from financing activities totaled $388.03 million, up from $132.00 million[28] - Net cash flow from financing activities improved to $301.29 million, compared to a negative $28.41 million previously[28] - The ending cash and cash equivalents balance increased to $522.00 million from $145.55 million, a rise of approximately 258.5%[28] - Cash received from tax refunds was $20.14 million, up from $18.08 million, reflecting an increase of about 11.4%[27] Operational Efficiency - The company attributed the profit growth to enhanced operational efficiency and cost optimization through refined management and technology upgrades[9] - The sales volume of biological preservatives and functional ingredients increased, contributing to the overall revenue growth despite a slight decline in operating revenue for the quarter[10] - Total operating costs decreased to ¥555,173,218.95 in 2025 from ¥577,385,792.61 in 2024, indicating a reduction of about 3.8%[22] Employee Stock Ownership Plan - The company approved a revised employee stock ownership plan, allowing for the purchase of up to 1,000,000 shares at a price of ¥8.39 per share, with a total funding limit of ¥8.39 million[15] - The company plans to maintain the employee stock ownership plan for a duration not exceeding 48 months[15] - The total number of participants in the employee stock ownership plan is capped at 44 individuals[15] Current Assets - As of September 30, 2025, the company's total current assets increased to ¥960,694,846.93 from ¥708,768,058.47 as of December 31, 2024, representing a growth of approximately 35.4%[19] - Cash and cash equivalents rose significantly to ¥549,241,271.05, up from ¥315,618,528.67, marking an increase of about 74.1%[19] - Accounts receivable increased to ¥151,833,993.78 from ¥136,631,018.06, reflecting a growth of approximately 11.1%[19] - The company's inventory decreased slightly to ¥194,888,229.31 from ¥197,536,174.76, a decline of about 1.3%[19] - The total non-current assets remained stable at ¥10,700,000.00, unchanged from the previous period[19] - The company's fixed assets increased to ¥459,573,253.69 from ¥432,020,992.02, indicating a growth of approximately 6.4%[19] Investment Income - The company reported a significant increase in investment income, which was ¥1,325,624.94 in 2025 compared to ¥3,015,295.08 in 2024, showing a decrease of about 56.1%[23]

证券代码：603079 证券简称：圣达生物 公告编号：2025-058 浙江圣达生物药业股份有限公司 2025年第三季度主要经营数据公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第3号行业信息披露：第十三 号——化工》及《上市公司自律监管指引第3号行业信息披露：第十四号——食 品制造》的要求，现将浙江圣达生物药业股份有限公司（以下简称"公司"） 2025年第三季度主要经营数据披露如下： 注：公司主要产品中，维生素产品包括生物素（折纯）、叶酸（折纯）；生物保鲜剂 及功能配料产品包括乳酸链球菌素、纳他霉素、聚赖氨酸和蔗糖发酵物等。 生物素（折纯）产量包含公司外购生物素粗品精制加工的生物素纯品。 二、报告期内主要产品销售地区分布基本情况 三、报告期内主要产品和原材料的价格变动情况 比下降17.06%；生物保鲜剂及功能配料平均销售价格较上年同期下降0.76%，环 比下降5.82%。 2、主要原材料价格（不含税）变动情况 第三季度，公司主要原材料三氨基盐平均采购价格较上年同期下降 23.3 ...

Core Insights - The company reported third-quarter revenue of 221 million, a year-on-year decrease of 1.71% [1] - Net profit for the third quarter was 15.53 million, showing a significant year-on-year increase of 199.63% [1] - For the first three quarters, the company achieved revenue of 621 million, reflecting a year-on-year growth of 2.04% [1] - Net profit for the first three quarters reached 53.34 million, marking a year-on-year increase of 146.04% [1]

Core Insights - The chemical products sector experienced a slight increase of 0.11% on October 24, with Boyuan Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3950.31, up 0.71%, while the Shenzhen Component Index closed at 13289.18, up 2.02% [1] Sector Performance - Boyuan Co., Ltd. (301617) closed at 102.79, with a significant increase of 14.34% and a trading volume of 91,000 shares, resulting in a transaction value of 902 million yuan [1] - Yahua Group (002497) saw a rise of 10.03%, closing at 17.88 with a trading volume of 1.2768 million shares [1] - Licheng Industrial (001218) increased by 6.97%, closing at 23.78 with a trading volume of 95,700 shares [1] - Guangdong Hongda (002683) rose by 4.77%, closing at 39.94 with a trading volume of 237,200 shares [1] - Other notable performers include Shengda Biological (603079) up 4.29%, Jianlong Micro-Nano (688357) up 4.04%, and Gaodian New Materials (300200) up 3.86% [1] Capital Flow - The chemical products sector saw a net outflow of 291 million yuan from main funds, while retail investors contributed a net inflow of 379 million yuan [1]

证券代码：603079 证券简称：圣达生物 公告编号：2025-057 浙江圣达生物药业股份有限公司 关于使用闲置募集资金进行现金管理的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基本情况 | 投资金额 | 8,000.00 万元 | | --- | --- | | 投资种类 | 中国建设银行浙江分行单位人民币定制型结构性存款 | | 资金来源 | 募集资金 | 已履行及拟履行的审议程序 浙江圣达生物药业股份有限公司（以下简称"公司"）于 2025 年 7 月 7 日召 开第四届董事会第十八次会议和第四届监事会第十六次会议，审议通过了《关于 使用闲置募集资金进行现金管理的议案》，同意公司及子公司使用额度不超过人 民币 23,000.00 万元的暂时闲置募集资金进行现金管理，用于购买安全性高、流 动性好、有保本约定、产品期限不超过 12 个月的银行等金融机构现金管理产品 （包括但不限于结构性存款、大额存单等）。在上述期限及额度内，资金可滚动 使用，并授权公司董事长最终审定并签署相关实施协议或者合同等 ...

Core Viewpoint - Zhejiang Sandar Biopharmaceutical Co., Ltd. is set to hold a Q3 2025 earnings presentation on November 5, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Earnings Presentation Details - The earnings presentation will take place on November 5, 2025, from 10:00 to 11:00 AM [5]. - The event will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [4][5]. - Investors can submit questions from October 29, 2025, to November 4, 2025, before 4:00 PM through the Roadshow Center website or via the company's email [2][4]. Group 2: Financial Management - The company approved the use of up to RMB 230 million of temporarily idle raised funds for cash management, focusing on safe and liquid financial products with a maturity of no more than 12 months [7]. - On August 29, 2025, the company purchased RMB 80 million in structured deposits from China Construction Bank, which matured on September 30, 2025, returning the principal and a yield of RMB 12.34 thousand [8]. Group 3: Employee Stock Ownership Plan - The first meeting of the 2024 Employee Stock Ownership Plan was held on October 9, 2025, with full attendance from the holders representing 100% of the plan's shares [9][10]. - A management committee was established to oversee the daily management of the employee stock ownership plan, consisting of three members [11]. - The committee was authorized to handle various responsibilities related to the employee stock ownership plan, including convening meetings and managing shareholder rights [12][13][14].

浙江圣达生物药业股份有限公司 关于召开2025年第三季度业绩说明会的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 05 日（星期三）10:00-11:00 证券代码：603079 证券简称：圣达生物 公告编号：2025-056 （三）会议召开方式：上证路演中心网络互动 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow. sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 29 日（星期三）至 11 月 04 日(星期二)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@sd-pharm.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 浙江圣达生物药业股份有限公司（以下简称"公司"）将于2025年10月30 日发布公司2025年第三季度报告，为便于广大投资者更全面深入地了解公司 2025年第三季度经营成果、财务状况，公司计划于2025年1 ...